ClinicalTrials.gg
CompletedNCT00710255Updated Oct 31, 2016

Role of Leukotrienes and Adenosine in Hyperpnea-induced Bronchospasm

An observational study in Asthma, Exercise Induced, sponsored by University of Vermont. Completed at 1 site in United States. Open to participants aged 12 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-10-31.

Sponsored by University of Vermont · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
8
Ages
12 Years to 75 Years
Sex
All
01

Study summary

This research is being conducted to help us better understand what causes exercise induced asthma. The investigators hypothesize that two types of chemicals, cysteinyl leukotrienes and adenosine, play an important role. The investigators will be measuring these chemicals in the exhaled breath of volunteers with exercise induced asthma as they undergo a test to mimic exercise induced asthma. The investigators will determine how the levels of these chemicals change in association with how lung function changes before, during and after an episode of exercise induced asthma.

02

Conditions studied

  • Asthma, Exercise Induced

Keywords

  • Asthma
  • Exercise induced bronchospasm
  • Hyperpnea induced bronchospasm
  • leukotrienes
  • adenosine
  • exhaled breath condensate
03

In context

Asthma, Exercise-Induced

52 studies on the registry are indexed under Asthma, Exercise-Induced; 3 are open to participants now.

Browse Asthma, Exercise-Induced studies →

Lead sponsor

University of Vermont is the lead sponsor of 221 studies on the registry; 27 are open to participants now.

Of its 17 completed or terminated interventional studies of FDA-regulated products, 9 (53%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Asthmatics with exercise induced bronchospasm

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Physician diagnosed asthma
  • Age 12-75 yrs
  • > 70% predicted
  • HIB response > 10 %
  • No smoking last 6 mo and \< 10 pack yrs
  • No URI last 4 weeks
  • No asthma exacerbation last 4 weks
  • Able to withhold SABA > 8 hrs and LABA > 24 hrs

Exclusion criteria

Exclusion Criteria:

  • Other lung disease
  • Cardiac disease or other condition that would preclude safe participation, on theophylline or leukotriene modifiers
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
8 participants (actual)

Groups and cohorts

  • Asthmatics

    Asthmatics with exercise induced bronchospasm

    Procedure: Hyperpnea challenge

Interventions

  • ProcedureHyperpnea challenge

    5 minutes of dry air hyperpnea to induce bronchospasm

06

What researchers measure

Primary outcomes

  1. Change in level of cystLTs and adenosine

    Time frame: Before and after hyperpnea challenge

Secondary outcomes

  1. Change in pH of EBC and change in pulmonary function

    Time frame: Before and after hyperpnea challenge

07

Study locations

1 site
  • Vermont Lung Center
    Colchester, Vermont 05446, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2007, a primary completion of Mar 2009 and a completion of Jul 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2008
First posted
Jul 4, 2008
Start
Oct 2007
Primary completionActual
Mar 2009
CompletionActual
Jul 2009
Last update
Oct 31, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 31, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00710255
Responsible party
David Kaminsky, MD (Professor, University of Vermont) — Principal investigator
First posted
Jul 4, 2008
Start date
Oct 2007
Primary completion
Mar 2009
Completion
Jul 2009
Last update
Oct 31, 2016

Study contacts

David A. Kaminsky, MD
principal investigator · University of Vermont

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion